ProMIS Neurosciences Announces $75 Million PIPE Financing
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ProMIS Neurosciences ( (PMN) ) has provided an update.
On January 30, 2026, ProMIS Neurosciences announced it had entered into a private investment in public equity financing, signing a securities purchase agreement on January 29, 2026 with new and existing institutional and accredited investors to raise approximately $75 million in upfront gross proceeds through the sale of 6,815,296 common shares and accompanying warrants, with the potential to raise up to a total of about $175 million if all warrants are exercised. The PIPE, co-led by Janus Henderson and Ally Bridge Group and also involving several specialized healthcare investors plus ProMIS management and directors, is expected to close on February 3, 2026 and extend the company’s cash runway into 2028, funding completion of its Phase 1b Alzheimer’s study of PMN310, advancing a subcutaneous formulation of the drug, and supporting key clinical milestones, including blinded six‑month top-line data anticipated in mid‑2026 and 12‑month top-line data toward the end of 2026.
The most recent analyst rating on (PMN) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Neutral.
The score is held down primarily by weak financial performance: no revenue, large ongoing losses, and significant negative operating/free cash flow implying continued financing and dilution risk. Technicals provide some support via improving short-term momentum, while valuation remains difficult to justify with negative earnings and no dividend. Corporate events are modestly positive (Nasdaq compliance regained, board strengthening) but secondary to the cash-burn profile.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
ProMIS Neurosciences Inc., based in Cambridge, Massachusetts and Toronto, is a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies and vaccines that selectively target toxic misfolded protein oligomers implicated in neurodegenerative and other misfolded protein diseases. Using its proprietary EpiSelect target discovery engine to identify disease-specific epitopes, the company is developing candidates for conditions including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, multiple system atrophy and Parkinson’s disease.
Average Trading Volume: 27,509
Technical Sentiment Signal: Sell
Current Market Cap: $26M
Learn more about PMN stock on TipRanks’ Stock Analysis page.
